Curis, Inc. (NASDAQ:CRIS) – Research analysts at SunTrust Banks lowered their FY2017 EPS estimates for Curis in a report released on Tuesday. SunTrust Banks analyst P. Lawson now expects that the biotechnology company will post earnings of ($0.40) per share for the year, down from their previous estimate of ($0.35). SunTrust Banks also issued estimates for Curis’ Q4 2017 earnings at ($0.08) EPS, Q1 2018 earnings at ($0.07) EPS, Q2 2018 earnings at ($0.08) EPS, Q3 2018 earnings at ($0.08) EPS, Q4 2018 earnings at ($0.08) EPS, FY2018 earnings at ($0.31) EPS, FY2019 earnings at ($0.29) EPS and FY2020 earnings at ($0.18) EPS.
Other equities research analysts have also recently issued reports about the stock. Guggenheim started coverage on shares of Curis in a research report on Monday, October 23rd. They set a “buy” rating and a $7.00 price target on the stock. Zacks Investment Research raised shares of Curis from a “sell” rating to a “hold” rating in a research report on Monday, October 16th. ValuEngine raised shares of Curis from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, BidaskClub raised shares of Curis from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 17th. Three equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. Curis has an average rating of “Hold” and a consensus price target of $6.50.
ILLEGAL ACTIVITY WARNING: “SunTrust Banks Weighs in on Curis, Inc.’s FY2017 Earnings (CRIS)” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2017/11/12/suntrust-banks-weighs-in-on-curis-inc-s-fy2017-earnings-cris.html.
Shares of Curis (NASDAQ:CRIS) opened at $1.23 on Friday. The company has a debt-to-equity ratio of 1.24, a current ratio of 5.15 and a quick ratio of 3.72. Curis has a 52-week low of $1.20 and a 52-week high of $3.72.
Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The company had revenue of $2.44 million during the quarter, compared to the consensus estimate of $2.19 million. Curis had a negative net margin of 629.29% and a negative return on equity of 250.58%. During the same period in the prior year, the firm posted ($0.21) earnings per share. The company’s revenue was up 38.6% compared to the same quarter last year.
Hedge funds have recently modified their holdings of the company. FNY Partners Fund LP raised its holdings in shares of Curis by 350.0% in the 3rd quarter. FNY Partners Fund LP now owns 67,500 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 52,500 shares during the period. Bank of America Corp DE raised its holdings in shares of Curis by 58.7% in the 1st quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 13,448 shares during the period. Prudential Financial Inc. bought a new stake in shares of Curis in the 1st quarter valued at about $105,000. OxFORD Asset Management LLP bought a new stake in shares of Curis in the 2nd quarter valued at about $115,000. Finally, Voya Investment Management LLC raised its holdings in shares of Curis by 21.8% in the 2nd quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 12,207 shares during the period. 44.67% of the stock is currently owned by institutional investors.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.